cyrilzakka/clinical-trials huggingface dataset:
S-Metoprolol XR 25-50 mg Tablets vs Metoprolol Zok 50-100 mg Tablets in Hypertension Patients.

The aim of this study is to compare the efficacy and safety of S-Metoprolol XR 25 and 50 mg Film Coated Tablets and Beloc® (Metoprolol) Zok 50 and 100 mg Controlled Release Film Tablets administered once daily, in the treatment of hypertension.


Eligibility Criteria:
Inclusion Criteria:

* Male or female patients: between the ages of 18-70,
* Stage 1 and 2 hypertension patients who have not received any antihypertensive treatment in the past month \* (≥ 140 mmHg SKB \<180 mmHg, ≥ 90 mmHg DKB \<110 mmHg,
* Patients with minute heart rate ≥ 70 / min,
* Patients followed up with outpatient treatment,
* Patients who give written informed consent without any influence, (Stage 1 Hypertension; SKB: 140-159 mmHg and DKB: 90-99 mmHg, Stage 2 Hypertension; SKB: 160--179 mmHg and DKB: 100--109 mmHg)

Exclusion Criteria:

* Pregnant patients or breastfeeding mothers or women with childbearing potential who do not use any effective contraceptive methods,
* Patients with allergies or hypersensitivity to betabloker drugs,
* Patients who have received antihypertensive treatment in the past month,
* Patients with secondary hypertension,
* Patients who were followed up for the following diseases from the beginning of the study until the last 12 months,

  * Severe hypertension (SKB\> 180 mmHg and / or DKB\> 110 mmHg),
  * Myocardial infarction,
  * NYHA stage 2-4 heart failure,
  * Patients with a history of cerebrovascular disease, previous ischemic attack, encephalopathy,
  * Patients undergoing percutaneous coronary intervention or coronary artery bypass surgery,
  * 2nd or 3rd degree heart block or symptomatic arrhythmia without pacemaker,
  * Clinically significant heart valve disease,
  * Simultaneous life-threatening potential or symptomatic arrhythmia,
  * Simultaneous unstable angina pectoris,
  * Type 1 DM,
  * Atrial fibrillation,
  * Uncontrollable Type 2 DM (HbA1C\> 7%),
* Patients with significant liver disease (initial ALT, AST\> 2xULN, esophageal varices, portocaval shunt),
* Patients with significant kidney disease (GFR \<60 ml / min according to the Cockcroft-Gault formula),
* Patients with volume depletion,
* Patients with pancreatic disease,
* Patients with gastrointestinal disease affecting absorption,
* Drug/substance and alcohol abuse in the last 12 months,
* Patients with central nervous system disease and using drugs for this reason,
* A history of incompatibility with medical regimens, or patients' unwillingness to comply with the study protocol,
* Patients directly involved in the management of this protocol.
Short- and Long-term Outcomes of Robotic vs Laparoscopic Right Colon Cancer: a 10-year Single-center Retrospective Study

The goal of this observational study is to evaluate the short-term outcomes and long-term outcomes of robot-assisted right colon group for cancer compared to laparoscopic-assisted right colon group. This is a large sample study based on ten years of clinical data. The main question it aims to answer is: What are the advantages of da Vinci robot right hemicolectomy compared to laparoscopic right hemicolectomy, and is there a difference in long-term efficacy between the two methods.

Colorectal cancer (CRC) is highly prevalent worldwide. In China, CRC ranks high among the population of men and women with cancer. The incidence and mortality rates of CRC are rising quickly in developing countries, and it is the fourth most deadly cancer in the world. In particular, the right colon cancer (RCC) is continuously growing in China, and the early symptoms of RCC are not typical. one of the most useful ways for RCC is surgical is a surgical operation. Along with the development of minimally invasive surgery, the use of laparoscopy for colon cancer is widely accepted and has become one symbolic surgical technology. Studies have demonstrated that laparoscopic colonic surgery is related to reduced pain after operation, shorter rehabilitation time, shorter length of hospital stay, reduced the time of ileus after surgery, and reduced surgical site infection.

Nevertheless, laparoscopic surgery also has its shortcoming, including a limited range of motion, slow learning and growth, and physiological tremor cannot be eliminated.The emergence of robots has broken the inherent disadvantage of laparoscopy. It has achieved similar or better results in previous studies. Based on these advantages, robotic surgery has received much attention from the surgeons. With the first robotic surgery in the field of colon cancer was reported in 2002, there are some studies proved the safety and feasibility by using robot,However, most studies with small sample sizes and with cases at a relatively early stage.

Therefore, the purpose of this study is to compare the short-term and long-term outcomes between RARC and LARC in the treatment of right colon cancer in our center.

Eligibility Criteria:
Inclusion Criteria:

1. The age is more than 18 years old and less than or equal to 85 years old
2. No distant metastasis (including pelvic cavity, peritoneum, liver, lung, brain, bone, distant lymph node metastasis, etc.) is judged by ultrasound, CT, PET-CT, etc
3. Preoperative colonoscopy showing that the tumor was located in the ileocecal region, ascending colon, hepatic flexure, or transverse colon with pathology showing malignancy
4. signed informed consent. -

Exclusion Criteria:

1. multiple primary colorectal cancer
2. recurrent right colon cancer
3. preoperative neoadjuvant chemotherapy
4. emergency surgery for intestinal obstruction, bleeding or perforation
5. incomplete data and missing follow-up data. -
Personalized Upper Extremity Rehabilitation for Persons With Stroke

Approximately 80% of individuals with chronic stroke present with long lasting upper extremity (UE) impairments. Advances in rehabilitation technology, such as robotics, virtual reality (VR) and neuromuscular electrical stimulation (NMES), have separately demonstrated their effectiveness in improving UE function of individuals with stroke. The potential to influence recovery may be further enhanced by combining these modalities in order to target motor deficits of the individual. Research has shown that not all persons with stroke may be able to recover hand function. In particular, such recovery depends on the integrity of the corticospinal tract (CST), which links the motor areas of the brain to the UE (and hand) musculature. Instead of using a 'one-size-fits-all' approach to UE rehabilitation, CST integrity will be assessed through transcranial magnetic stimulation (TMS), a non-invasive approach, and match the intervention to the individual's specific impairments. The perSonalized UPper Extremity Rehabilitation (SUPER) intervention is proposed, which combines robotics, VR activities, and NMES. The objectives of this study are to determine the feasibility of the SUPER intervention in individuals with moderate/severe stroke. Stroke participants will receive a 5-week intervention (3x per week) combining robotic therapy and VR activities, based on their functional level. Those with low potential for hand recovery will receive an intervention focussing on elbow and shoulder movements. For those with a good potential for hand recovery, the last 30 minutes of the robotic or VR session will be complemented by muscle-triggered NMES. Feasibility indicators associated with process, resources, management and treatment will be measured. Outcomes of UE and hand function will include the Fugl-Meyer upper extremity assessment, the Box and Block test and the ABILHAND. It is expected that feasibility criteria will be met and that the SUPER intervention will lead to significant improvements in UE impairment compared to a waitlist group.


Eligibility Criteria:
Inclusion Criteria:

* ischemic or hemorrhagic stroke
* moderate to severe UE impairment (score between 2 and 4 out of 7 on the Chedoke-McMaster each of the arm and hand components
* at least 3 months post stroke
* no longer receiving rehabilitation services.

Exclusion Criteria:

* medical instability
* marked cognitive deficits (MiniCog score 2 or lower)
* uncorrected visual impairments
* shoulder pain that would limit participation in the study
* severe spasticity at the affected UE
Threshold Dose Distribution for Pistachio Allergy

The main objective of this study is to describe the distribution of reactogenic thresholds for pistachio. The secondary objectives are to 1) describe the clinical severity of allergic reactions to pistachio in an oral challenge test, 2) compare the reactogenic thresholds of pistachio and cashew nut on matched data and 3) evaluate predictive factors of a low reactogenic threshold

Nuts, including almonds, walnuts, cashews, pistachio and hazelnut, are among the food allergens most frequently involved in food allergies in children with an estimated prevalence. between 0.05 and 4.9%.

According to data from the Allergo-Vigilance Network, peanuts and the group of nuts, led by cashews, are alone responsible for 51.4% of food anaphylaxis in children.

The pistachio belongs to the same botanical family as the cashew nut (Anacardiumouest) and the mango (Mangifera indica): the anacardiaceae. Botanically, pistachio and cashew are closely related and can both be responsible for moderate to severe immediate allergic reactions. Furthermore, in a previous publication by the team, co-sensitization to pistachio was observed in 98% of children allergic to cashew nuts with only 34% confirmed allergic to pistachio.

In the case of allergy to both anacardiaceae, in a small number of patients, the investigators reported a reactogenic threshold for pistachio greater than or equal to that for cashew nuts.

To our knowledge, there is currently only one study that has evaluated the reactogenic threshold for pistachio, compared to other nuts.

Eligibility Criteria:
Inclusion Criteria:

* Patients under 18 years of age who had a positive pistachio challenge test between January 2021 and December 2023, in the pediatric allergology unit of the Nancy CHRU.

Exclusion Criteria:

* Patients who had a questionable oral pistachio provocation test.
* Patients who had a negative pistachio oral provocation test.
The Relationship Between Oxytocin Level and Postpartum Depression

There are studies in the literature that associate oxytocin level with postpartum depression. This study was carried out to investigate the relationship between oxytocin levels measured during pregnancy and postpartum depression symptoms.

Introduction and purpose: There are studies in the literature that associate oxytocin level with postpartum depression. This study was carried out to investigate the relationship between oxytocin levels measured during pregnancy and postpartum depression symptoms.

Method: The study was conducted with 70 women who met the research criteria. Data collection was done in two interviews. The first meeting is 30-38 at the week of gestation, the second interview is 4-12 at the week of postpartum. It was done between weeks. In each interview, a data collection form was applied first and then a saliva sample was taken. Data collection form; The questions prepared by the researchers consisted of the Edinburgh Postnatal Depression Scale (EPDS) and Beck Depression Inventory (BDI). The data were analyzed using SPSS 22.0 program and the significance value was taken as p \<0.05.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older, and having a pregnancy of 30 weeks or more

Exclusion Criteria:

* previous mental illness history, miscarriage or stillbirth history, multiple pregnancy, fetal malformation, antidepressant or anxiolytic drug use, existing chronic disease,preterm labor is the development of maternal or neonatal complications at birth, hospitalization in the neonatal intensive care unit or congenital disease.
Janus Kinase 1 in Vitiligo & Psoriasis

Assessment of the level of JAK1 in both vitiligo and psoriasis patients before and after treatment with NB-UVB which is considered a gold standard therapy for both diseases.


Eligibility Criteria:
Inclusion Criteria:

* age above 12 years of age.
* psoriasis vulgaris or non-segmental vitiligo
* patients who received no systemic or topical treatment at least 6 weeks prior to enrollment into the study.

Exclusion Criteria:

* psoriasis patients with erythrodermic psoriasis, pustular psoriasis or associated psoriatic arthritis
* vitiligo patients with segmental or universal vitiligo were excluded from the study.
* any patient with a photosensitive disorder or any contraindication to phototherapy exposure, e.g., history or presence of malignant or premalignant skin lesions.
Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery Registry

This was a retrospective observational cohort study. This study was a secondary analysis of individuals with sickle cell disease (SCD) enrolled in the GRNDaD registry.


Eligibility Criteria:
Inclusion criteria:

* Diagnosis of SCD.
* Signed consent to participate in GRNDaD registry.

Exclusion criteria:

• None identified at this time.
Study Evaluating the Pronostic Value of Vascular Refilling Rate on Mortality in Chronic Kidney Disease Patients on Dialysis

Aim of this study is to evaluate in a population of chronic kidney disease patients on dialysis (Stage 5D) during an observational period of 3 years:

* the prognostic value of vascular refilling rate on mortality and on the occurrence of i) cardiovascular events and ii) hospitalization number
* the prognostic value of interdialytic weight gain on mortality and on the occurrence of i) cardiovascular events and ii) hospitalization number
* the prognostic value of perdialytic weight loss on mortality and on the occurrence of i) cardiovascular events and ii) hospitalization number.


Eligibility Criteria:
Inclusion criteria:

* Chronic Kidney Disease patient on dialysis (stage 5D) since at least september 2017 (3 months prior to study start date)
* Anuric patient

Exclusion criteria:

- Chronic Kidney Disease patient on dialysis with residual kidney function
DHA Brain Delivery Trial

Carrying the APOE ɛ4 allele is the strongest genetic risk factor for developing Alzheimer's disease. The goal of this project is to identify whether carrying the APOE ɛ4 allele is associated with reduced delivery of DHA to the brain. This information will help us identify the target population that could benefit from DHA supplementation to prevent cognitive decline.

The Brain DHA Delivery Trial will examine the effect of APOE genotype on the changes of cerebrospinal fluid (CSF) DHA to Arachidonic acid (AA) ratio in 184 cognitively healthy older individuals in response to DHA supplementation. Randomized clinical trials have yielded mixed results on the effect DHA supplementation on cognitive outcomes. This study asks the critical question of whether DHA gets into the brain in sufficient amounts after supplementation, and whether APOE genotype affects brain penetrance.

This trial will also test the effect of DHA supplementation on changes in brain structural and functional connectivity assessed by MRI, and changes in cognition after two years of supplementation in all 368 participants.

Eligibility Criteria:
Inclusion Criteria:

* Age: ≥ 55 and ≤ 80
* At least one dementia risk factor (obesity, education years, hypertension, hyperlipidemia)
* Mini-Mental State Examination (MMSE) ≥ 25
* Logical Memory II delayed recall score ≥ 6 and ≤ 18 .

Exclusion Criteria:

* Diagnosis of dementia as assessed by the investigator
* Use of omega-3 preparations in the last 3 months
* \> 200 mg/day of DHA consumption using a validated questionnaire
* Use of donepezil, rivastigmine, galantamine and/or memantine
* Alcohol or drug abuse
* A concomitant serious disease such as active cancer treatment or HIV.
* Participation in a clinical trial in the last 30 days
* Use of anticoagulants such as Plavix or Coumadin or the newer generation blood thinners.
Effects of Open and Closed System Suctioning on Suctioning Frequency and Amount of Secretion

Tracheal suctioning is a process which is often applied to patients' care who have an artificial airway and whose respiration is achieved via mechanical ventilation. When secretions are not cleaned enough, it causes a variety of complications in the patient from hypoxemia to infection.

It is reported that the studies with nurses in clinical practice have shown that they have opinions such as the closed system does not suction the patients effectively as the open system does; it remains incapable in removing secretions, thus the suctioning process is being applied more frequently.

Therefore this study is designed to examine the amount of secretions and frequency of suctioning as a result of open and closed suctioning systems.

Patients will be monitored for two days. On the first day, the patient will be followed up with an open system and the second day closed suctioning system will be used, or the patient will be followed up with a closed system on the first day and followed with an open system on the second day. The patients are randomly allocated on the first follow up days. The follow-up period has two consecutive days. suctioning will be performed for 12 hours in one day. The number of suctions will be recorded. The amount of secretion will be accumulated in the mucus collection vessel. At the end of the day, the secretion will be weighed with precision weighing.

Eligibility Criteria:
Inclusion Criteria:

* orally intubated in first 96 hours
* stabilized patients in conditionally
* platelets \> 50.000
* not have hemorrhagic secretions

Exclusion Criteria:

* hemodynamically unstabilized patients
Predictive Value of FDG PET/CT, DWI and DCE-MRI Scans for Non-small Cell Lung Cancer Patients Receiving Chemotherapy

In this prospective study, the investigators will evaluate and compare the usefulness of functional and volumetric informations obtained by 18F-FDG PET and MRI before and after the palliative chemotherapy with the aim of predicting tumor response and prognosis in patients with advanced Non-small Cell Lung Cancer (NSCLC).

Study cohort will undergo PET/CT and MRI scans prior to chemotherapy and after the first chemotherapy cycle. MRI scans include DCE-MRI and DWI. The following parameters will be calculated using these values:

1. Metabolic parameters on FDG-PET A. SUV change ratio (SCR) = SUVpost/SUVpre B. MTV change ratio (VCR) = MTVpost/pre C. TLG change ratio = SCR X VCR
2. Perfusion parameters on DCE-MRI A. Kep B. K-trans C. ve
3. Diffusion parameters on DWI A. Mean ADC B. fDM

Eligibility Criteria:
Inclusion Criteria:

* Histologically proven NSCLC
* Newly diagnosed Stage stage IV
* Participant is being considered for the chemotherapy with EGFR TKI as a first line therapy
* At least one measurable primary or other intrathoracic lesion \>= 2cm, according to RECIST
* Performance status of 0 to 2 on the ECOG scale
* Age 18 years or older
* Able to tolerable PET/CT and MRI imaging required by protocol
* Able to give study-specific informed consent

Exclusion Criteria:

* Pure bronchioloalveolar cell carcinoma histology
* Thoracic radiotherapy, lung surgery or chemotherapy within three months prior to inclusion in the study
* Poorly controlled diabetes
* Prior malignancy
Investigation of Dynamic Hyperinflation and Its Relationship With Functional Exercise Capacity in Children With Bronchiectasis

Prevalence of dynamic hyperinflation and its relationship with functional exercise capacity will be evaluated in children with bronchiectasis.

Exercise or hyperpnea-induced air trapping is referred to as dynamic hyperinflation. In the presence of high resistance to expiratory flows and short expiratory times, the respiratory system is unable to return to its resting volume at the end of exhalation. The positive pressure within regions of hyperinflated lung raises the mean intrathoracic pressure and causes the inspiratory muscles to operate at a higher than resting lung volume. Thus, dynamic hyperinflation places the respiratory muscles at a considerable mechanical disadvantage and further impairs respiratory function. Dynamic hyperinflation is considered to be a key determinant of exercise capacity in patients with obstructive lung diseases. Although bronchiectasis is one of the obstructive lung diseases, the presence of dynamic hyperinflation in these patients has not been adequately investigated. Management guidelines of bronchiectasis state that imaging methods or pulmonary function tests alone is not sufficient to determine the disease burden and prognosis in these patients, so they recommend including detailed evaluation of exercise tolerance in the management of bronchiectasis. Aim of this study is to investigate the prevalence of dynamic hyperinflation and its relationship with functional exercise capacity in children with bronchiectasis.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of bronchiectasis

Exclusion Criteria:

* Hospitalization history during past month
* Diagnosis of any other chronic childhood diseases such as cerebral palsy or neuromuscular diseases which may impede exercise tolerance
Age-Related Changes in Stress Hormone Regulation

Studies investigating physiological processes involved in aging-related deficits in regulation of stress hormone systems.


Eligibility Criteria:
Exclusion Criteria:

* History of major psychiatric disorders,
* Neurologic disorder affecting cognitive function,
* Unstable medical problems,
* Medications including antidepressants, neuroleptics, anxiolytics, CNS stimulants, narcotic analgesics, anti-convulsants,
* Drugs effecting HPA axis function,
* Vision and hearing deficits,
* Undergoing major life event within one month or
* Loss of family member within 6 months.